Trial Profile
Multicenter,Randomized,Double-blind,Placebo,Parallel-controlled,Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2021
Price :
$35
*
At a glance
- Drugs Toludesvenlafaxine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Luye Pharma Group
- 23 Dec 2021 According to a Luye Pharma media release, Professor Zhang Hongyan from the Peking University Sixth Hospital, is a principal investigator of this study.
- 23 Dec 2021 According to a Luye Pharma media release, data from this study were presented at the 19th National Psychiatry Conference of the Chinese Medical Association.
- 23 Dec 2021 Top-Line results presented in a Luye Pharma media release.